Postischemic delayed Holmes' tremor responding to low-dose cabergoline [6]

Movement Disorders

Volumn 21, Issue 5, 2006, Pages 733-734

  Akkus, Dilek Evyapan ^a   Diramali, Azize Banu ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CARBIDOPA PLUS LEVODOPA;

ADULT; ANAMNESIS; BRAIN INFARCTION; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HOLMES TREMOR; HUMAN; LETTER; LOW DRUG DOSE; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR;

ANTIPARKINSON AGENTS; BRAIN STEM INFARCTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; TREMOR;

EID: 33646948219     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20862     Document Type: Letter

References (7)

1. Elble RJ. The pathophysiology of tremor. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw-Hill; 1997. p 405-417.
2. Yang YW, Chang FC, Tsai CH, et al. Clinical and magnetic resonance imaging manifestations of Holmes tremor. Acta Neurol Taiwan 2005;14:9-15.
3. Remy P, de Recondo A, Defer G, et al. Peduncular "rubral" tremor and dopaminergic denervation: a PET study. Neurology 1995;45: 472-477.
4. Camps M, Cortes R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989;28:275-290.
5. Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:685-689.
6. Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 2001;46(Suppl. 1):18-23.
7. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-788.